Computational models now touch every major stage of longevity drug discovery, from finding aging-related targets to designing entirely new compounds. The core division of labor is straightforward: predictive models such as molecular docking evaluate how existing compounds interact with biological targets, while generative AI models create novel molecular structures and surface new targets by mining vast datasets. Together, they compress a pipeline that traditionally relied on slow, expensive laboratory screening into a faster, iterative workflow in which computers propose and experiments verify.
Introduction to Computational Drug Discovery for Longevity
Traditional drug development is expensive and slow, and aging compounds that problem in several ways: aging is a whole-organism, multi-mechanism process, so the search space of possible targets and compounds is unusually large. Computational approaches offer an effective alternative to time-consuming experimental methods for determining molecular structures and screening chemical libraries at high throughput. In aging research specifically, a layered technology stack has emerged. As a review of deep learning and generative AI in aging research describes it, machine learning provides foundational methods for biomarker identification and biological age prediction; deep learning adds neural network architectures that analyze complex, multimodal datasets; and generative AI extends these capabilities, "enabling synthetic data generation, multimodal biomarker creation, and advanced applications in drug discovery and aging-related interventions."





